Customer Service Representative
About the job
- A secondary-school diploma is required.
- At least 2–3 years of experience in similar roles is required.
- Good knowledge of Microsoft Office is required.
- Good knowledge of SAP is required.
- Good knowledge of English is required.
- The role requires precision, organization, customer-service orientation, the ability to manage priorities and deadlines, communication and interpersonal skills, and a proactive problem-solving approach.
- Manage the end-to-end customer order process from receipt through fulfillment.
- Enter and verify orders in SAP.
- Monitor order progress and compliance with timelines.
- Communicate delays or issues to customers.
- Coordinate activities required to prepare shipments.
- Prepare invoices and shipping documentation.
- Collaborate with freight forwarders and logistics partners.
- Handle specific requests and pre-sales and after-sales issues.
- Manage returns according to company procedures.
About the company
LivaNova makes devices for heart surgery and neuromodulation therapies. Its neuromodulation products use an implanted generator with a lead that delivers electrical stimulation to the vagus nerve to help treat epilepsy and difficult-to-treat depression. In cardiac care, its devices support surgeons and clinicians during heart procedures, while the company has narrowed its portfolio to focus on these core areas. The goal is to improve outcomes for epilepsy and cardiac surgery and pursue growth in related areas like sleep apnea therapy.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
2015
Get referred to LivaNova
See people who can refer or advise you
Simplify's Take
What believers are saying
- 2Q 2026 revenue guidance rose to 8%–9%, driven by cardiopulmonary and epilepsy.
- January 2026 Medicare reimbursement increases boosted VNS economics for epilepsy procedures.
- Next-generation MRI-compatible aura6000 is targeted for 2027, expanding the OSA commercial runway.
What critics are saying
- Third-party oxygenator and component shortages still constrain Essenz output and 2026 growth.
- Heater-cooler litigation payments hit cash flow in 2026, with another $400 million expected.
- Inspire and Nyxoah pressure OSA adoption, while CMS still delays treatment-resistant depression coverage.
What makes LivaNova unique
- March 2026 aura6000 FDA approval gave LivaNova unique hypoglossal stimulation without CCC warning.
- Essenz heart-lung machines and consumables anchor cardiopulmonary scale, with China launch in August 2025.
- PolySync reprogramming lifted OSA response to 84.5%, strengthening LivaNova's differentiated platform economics.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Employee Stock Purchase Plan
Flexible Work Hours
Paid Vacation
Company News
LivaNova director Francesco Bianchi sold 1,650 ordinary shares for $131,500 on 31 August 2026, according to an SEC Form 4 filing. The shares were sold at $79.72 each, whilst the stock closed at $80.16 the following day. The sale represented 17% of Bianchi's directly held shares prior to the transaction. Following the disposition, the director now holds 7,934 shares directly. LivaNova develops therapeutic medical devices across three segments: Cardiopulmonary products including oxygenators and heart-lung machines, Neuromodulation devices such as the VNS Therapy System, and Advanced Therapies solutions. The company has a market capitalisation of $4.3 billion and generated $1.5 billion in revenue over the trailing twelve months.
LivaNova has announced that its PolySync programming algorithm achieved an 84.5% cumulative response rate in patients with moderate to severe obstructive sleep apnea treated with proximal hypoglossal nerve stimulation. The findings were presented at SLEEP 2026 by lead author Alan Schwartz. The results build on LivaNova's OSPREY trial, which reported a 65% responder rate after 12 months. In the PolySync substudy, patients who initially did not respond underwent reprogramming using simultaneous-contact stimulation, converting most into responders and significantly improving outcomes. The approach was well tolerated with no serious adverse events. PolySync will be available with LivaNova's commercial product. The company is preparing its next-generation obstructive sleep apnea device for FDA submission in the second half of 2026, featuring MRI compatibility and rechargeable battery technology.
LivaNova, a medical technology company, has appointed Jette Nygaard-Andersen to its Board of Directors following its Annual General Meeting on 10 June. Nygaard-Andersen currently chairs Coloplast A/S, a Danish medical device company, and previously served as CEO of Entain plc and in senior roles at Modern Times Group AB. The appointment coincides with Dr Sharon O'Kane stepping down after 10 years on the board. Brooke Story will succeed O'Kane as Chair of the Nominating and Corporate Governance Committee, whilst Peter Wilver assumes leadership of the Compensation and Human Capital Management Committee. LivaNova develops medical solutions for neurological and cardiac conditions, employs approximately 3,300 people, and operates in over 100 countries.
LivaNova reported 10% organic revenue growth in Q2 2025, driven by cardiopulmonary business momentum and solid neuromodulation performance across all regions. The company also delivered operating margin expansion and strong cash generation. The company announced key clinical milestones, including long-term results from the CORE-VNS study showing an 80% median seizure reduction at 36 months for focal onset seizures and 95% for focal to bilateral tonic-clonic seizures in drug-resistant epilepsy patients. LivaNova initiated the process with CMS to seek national Medicare coverage for VNS therapy in treatment-resistant depression patients, supported by five peer-reviewed publications from the RECOVER study. The company's obstructive sleep apnea programme remains in FDA review, with management expressing confidence in its proximal hypoglossal nerve stimulation technology.
LivaNova reported 13% organic revenue growth in Q3 2025, driven by strong performance in cardiopulmonary and epilepsy businesses. The cardiopulmonary segment generated $203 million in revenue, up 16% year-over-year, with heart-lung machine revenue growing over 20%. The company saw accelerated placements of its Essenz heart-lung machines, with most installations in developed markets. LivaNova launched Essenz in China, its second-largest market, in August, with positive early feedback. However, expansion remains constrained by third-party component supply despite progressing manufacturing capacity plans. LivaNova unveiled a refreshed brand identity and new strategic framework, which will be detailed at its investor day on 12 November. The company is focusing on near-term performance whilst investing in core businesses and developing programmes for obstructive sleep apnoea.